Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer
Open Access
- 1 July 2024
- journal article
- review article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 16, 941-963
Abstract
Biliary tract cancer (BTC) represents a challenging malignancy characterized by aggressive behavior, high relapse rates, and poor prognosis. In recent years, immunotherapy has revolutionized the treatment landscape for various cancers, but its efficacy in BTC remains limited. This article provides a comprehensive overview of the advances in preclinical and clinical studies of immunotherapy for BTC. We explore the potential of immune checkpoint inhibitors in reshaping the management of BTC. Despite disappointing results thus far, ongoing clinical trials are investigating the combination of immunotherapy with other treatment modalities. Furthermore, research on the tumor microenvironment has unveiled novel targets for immunotherapeutic interventions. By understanding the current state of immunotherapy in BTC and highlighting future directions, this article aims to fuel further exploration and ultimately improve patient outcomes in this challenging disease.Keywords
This publication has 231 references indexed in Scilit:
- KRAS Allelic Variants in Biliary Tract CancersJAMA Network Open, 2024
- Survival benefit and biomarker of PD‐1 inhibitor combination therapy in first‐line of advanced biliary tract cancer: A retrospective studyCancer Medicine, 2023
- Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteinsCancer Communications, 2023
- Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancerCancer Medicine, 2022
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract CancerJAMA Oncology, 2020
- A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancerCancer, 2020
- Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012Cancer, 2020
- Biliary tract cancer incidence and trends in the United States by demographic group, 1999‐2013Cancer, 2019
- Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancerBritish Journal of Surgery, 2018
- Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinomaBritish Journal of Surgery, 2017